Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

Exit

PublicOTCBB:SNGX
Date10/2009
Raised
Post IPO Valuation

General Information

Websitesoligenix.com
Twitter@Soligenix_Inc
CategoryBioTech
Phone609-538-8200
Employees

Offices

Princeton, USA
29 Emmons Drive
Suite C-10
Princeton, NJ, 08540
USA

People

Funding

TOTAL $21.7M
FUNDING TOTAL $14.6M
Venture Round, 2/2009
$2.38M
Venture Round, 2/2009
$4.5M
Venture Round, 7/2010
Sigma-Tau
Downsview Capital
Rockmore Capital
OpusPoint Partners
Iroquois Capital
Dafna Capital Management
Brio Capital
Kingsbridge Capital
Rosalind Capital Partners
$5.9M
Seed, 5/2013
$1.5M
Grant, 2/2014
$300k
POST IPO FUNDING TOTAL $7.1M
Post IPO Equity, 6/2013
Third Security
$7.1M

Tags

Soligenix

Soligenix, Inc. is a late-stage research and development biopharmaceutical company focused on developing products to treat the life-threatening side effects of cancer treatment and serious gastrointestinal diseases where there remains an unmet medical need, as well as developing biodefense vaccines and therapeutics. The Company maintains two business segments: BioTherapeutics and BioDefense. Its BioTherapeutics business segment focuses to develop oral beclomethasone dipropionate (orBec or oral BDP) and other biotherapeutic products, including LPMTM Leuprolide. Its BioDefense business segment focuses to convert its ricin toxin vaccine and radiation injury program from early stage development to advanced development and manufacturing.

Recent Milestones

  • Dollar
    Soligenix received $300k in Grant funding. (2/16/14)
    Posted 2/16/14 at 8:51pm via genengnews.com
  • Check
    Soligenix — Soligenix announces $600,000 investment, up to $10.6M, by Lincoln Park Capital (11/21/13)
    Posted 11/21/13 at 10:32pm via njbiz.com
  • Check
    Soligenix — Soligenix Awarded NIAID Contract Valued up to $6.4 Million for the Development of OrbeShield' in GI ARS (9/25/13)
    Posted 9/25/13 at 4:10am via bioportfolio.com
  • Check
    Soligenix — Soligenix awarded federal contract worth up to $26M (9/19/13)
    Posted 9/19/13 at 9:43pm via njbiz.com
  • Dollar
    Soligenix received $7.1M in Post IPO Equity funding. (6/26/13)
    Posted 6/26/13 at 5:44am via pehub.com
  • Dollar
    Soligenix received $1.5M in Seed funding. (5/3/13)
    Posted 5/28/13 at 2:38am via sec.gov
  • Dollar
    Soligenix received $5.9M in Venture Round funding. (7/2/10)
    Posted 7/7/10 at 1:18am via sec.gov
  • Stock
    Went public with stock symbol OTCBB:SNGX. (10/9/09)
    Posted 7/7/10 at 1:18am
  • Dollar
    Soligenix received $4.5M in Venture Round funding. (2/25/09)
    Posted 2/5/14 at 2:13am via sec.gov
  • Dollar
    Soligenix received $2.38M in Venture Round funding. (2/3/09)
    Posted 2/4/14 at 3:11am via sec.gov
  • Check
    Posted 7/7/10 at 1:18am
  • Check
    Soligenix added Christopher J. Schaber as President and CEO.
    Posted 7/7/10 at 1:18am
  • Check
    Soligenix added Jerome Zeldis as Board Member.
    Posted 12/15/13 at 9:46am
  • Check
    Soligenix added Christopher P. Schnittker as Vice President – Administration, Corporate Secretary and Chief Accounting Officer.
    Posted 1/2/14 at 9:09am

Videos

Screenshots

Soligenix screenshot
Above: Home Page
Uploaded: 7/7/10

Stock Price

Sources

  1. SEC (sec.gov) [edit]
  2. SEC (sec.gov) [edit]
  3. SEC (sec.gov) [edit]
  4. SEC (sec.gov) [edit]
  5. Soligenix Closes IPO at $7.1 Mln (pehub.com) [edit]
  6. Soligenix Wins $300K Grant to Further Develop Melioidosis Treatment (genengnews.com) [edit]
  7. Soligenix awarded federal contract worth up to $26M (njbiz.com) [edit]
    Soligenix Awarded NIAID Contract Valued up to $6.4 Million for the Development of OrbeShield' in GI ARS (bioportfolio.com) [edit]
    Soligenix announces $600,000 investment, up to $10.6M, by Lincoln Park Capital (njbiz.com) [edit]
Edit This Page
Last Edited 2/22/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy